Clinical Trial Update: Increased Re-eradication Rate of Helicobacter Pylori by Adding N-acetylcystein or Metronidazole to the Triple Therapy [Phase 4]

View source ↗

Summary

A Phase 4 trial update reports that adding N-acetylcysteine or metronidazole to standard triple therapy may improve eradication rates of Helicobacter pylori.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Helicobacter Pylori Infection

Drugs mentioned

• METRONIDAZOLE (Metronidazole)
• N-acetylcysteine (N-acetylcysteine)

Snippet

Sponsor: Buddhist Tzu Chi General Hospital | Conditions: Bacterial Infection Due to Helicobacter Pylori (H. Pylori) | Phase 4 | Status: UNKNOWN